Arsenicals (Arsenic Compounds)

03/01/2012 - "Arsenic compounds have shown medical usefulness since they proved to be effective in causing complete remission of acute promyelocytic leukemia. "
10/15/1999 - "Arsenic compounds have recently been shown to induce high rates of complete remission in patients with acute promyelocytic leukemia (APL). "
06/01/2001 - "Arsenic compounds have been found to be effective in the treatment of acute promyelocytic leukemia through the downregulation of bcl-2 expression. "
01/01/2001 - "Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies."
08/15/2009 - "Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells."

11/01/2014 - "The effects of inorganic and organic arsenicals on proliferation, cell-cycle distribution, and apoptosis of all-transretinoic acid (ATRA)-resistant human promyelocytic leukemia HL-60 (HL-60-R2) cells were herein investigated. "
12/01/2011 - "Inorganic arsenic compounds are suggested as useful agents for treatment of T-lymphoblastoid leukemia."
12/01/2011 - "Organic arsenic compounds have no inhibitory activity on the leukemia cell proliferation. "
12/01/2011 - "Six organic arsenic compounds did not inhibit leukemia cell proliferation. "
12/01/2011 - "To investigate the effects of inorganic and organic arsenic compounds on human T-lymphoblastoid leukemia cells. "

06/01/2001 - "Arsenic compounds (As2O3 and As2S3) can inhibit growth and induce apoptosis in human ovarian and cervical cancer cells at clinically achievable concentrations, indicating that As2O3 and As2S3 could be effective in the treatment of gynecological cancer."
08/01/2014 - "The objective of the current study was to develop a polymeric micelle drug delivery system for efficient and controlled delivery of trivalent arsenicals to solid tumor cells. "
11/01/2010 - "This work reviews the available rodent studies considered relevant to carcinogenic assessment of arsenicals, taking advantage of the most recent review by the International Agency for Research on Cancer (IARC) that has not yet appeared as a full monograph but has been summarized (IARC, 2009 , IARC Special Report: Policy, Vol. "
01/01/2015 - "Arsenic compounds have modest cytotoxic activity in solid tumors. "
11/01/2012 - "The agglomerative DNA methylation changes induced by arsenicals appear to be common and clinically relevant events, since they occur in other human cancer cell lines and models of malignant transformation, as well as clinical cancer specimens. "

05/19/2014 - "When assessing the toxicity by exposing multiple myeloma cells to arsenicals externally, DMMTA(V)(GS) was found to be much less toxic than DMA(III)(GS) and DMMTA(V), potentially due to its limited uptake in the cells (10 and 16% of the uptakes of DMA(III)(GS) and DMMTA(V), respectively). "
11/01/2006 - "Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy."
11/01/2006 - "The use of arsenic compounds in the treatment of multiple myeloma (MM) is supported by the proposed mechanisms of action underlying the antitumor activity of arsenic and by preclinical studies showing antiproliferative and cytotoxic activities in cell culture and animal models. "
12/01/2006 - "The development of new generations of orally bioavailable inorganic, as well as new organic, arsenic compounds with improved toxicity profiles may bolster the therapeutic application of arsenic derivatives in hematologic malignancies such as leukemia, multiple myeloma and myelodysplastic syndromes."

12/01/2006 - "The development of new generations of orally bioavailable inorganic, as well as new organic, arsenic compounds with improved toxicity profiles may bolster the therapeutic application of arsenic derivatives in hematologic malignancies such as leukemia, multiple myeloma and myelodysplastic syndromes."
11/01/2006 - "Although the use of arsenic to treat hematologic cancers has been documented since the 19th century, widespread use of arsenic compounds in patients with hematologic malignancies did not occur until the 1990s, when several groups in China reported impressive clinical response rates in patients with acute promyelocytic leukemia who had received arsenic trioxide. "